Connection

Anand Sharma to Trastuzumab

Back to Details
This is a "connection" page, showing publications Anand Sharma has written about Trastuzumab.
Anand Sharma
Connection Strength
0.198
Trastuzumab
  1. Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2022 02; 23(2):259-269.
    View in: PubMed
    Score: 0.198
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.